HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

S 2242

an N-7-substituted acyclic nucleoside analog

Also Known As:

2-amino-7-((1,3-dihydroxy-2-propoxy)methyl)purine; S-2242; S2242

Networked: 9 relevant articles (2 outcomes, 0 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Purines: 651
      - S 2242: 9

Experts

1.	De Clercq, E: 3 articles (11/2005 - 01/2001)
2.	Sidwell, Robert W: 2 articles (12/2006 - 05/2002)
3.	Smee, Donald F: 2 articles (12/2006 - 05/2002)
4.	Naesens, L: 2 articles (11/2005 - 11/2001)
5.	Neyts, J: 2 articles (11/2001 - 01/2001)
6.	Evans, David H: 1 article (12/2006)
7.	Hostetler, Karl Y: 1 article (12/2006)
8.	Kornbluth, Richard S: 1 article (12/2006)
9.	Snarsky, Victoria: 1 article (12/2006)
10.	Lenaerts, L: 1 article (11/2005)

Related Diseases

1.	Herpesviridae Infections (Herpesvirus Infection) 01/01/1995 - "The efficacy of 2-amino-7-[(1,3-dihydroxy-2-propoxy)methyl]purine (S2242) was evaluated in several animal models for herpesvirus infections. " 11/01/2001 - "They were selected either because they are already approved for clinical use in the treatment of herpesvirus infections (acyclovir, valaciclovir, penciclovir, famciclovir, ganciclovir, brivudin, foscarnet and cidofovir) or have demonstrated marked activity against herpesviruses (lobucavir, H2G, A-5021, D/L-cyclohexenyl G and S2242). "
2.	Infections 05/01/2002 - "Overall, S2242 and HOE961 were found to be effective against cowpox virus infections in mice but were less potent than cidofovir. "
3.	Body Weight (Weight, Body) 11/01/2005 - "Treatment with cidofovir or S-2242 at a dose of 100 mg per kg of body weight resulted in a significant delay in MAV-1-related death, although these antivirals were unable to completely suppress virus replication despite continued drug treatment. " 01/01/2001 - "Mice that had been treated for 5 consecutive days via the subcutaneous (s.c.) route with 100 mg of the diacetate ester prodrug of S2242 (compound H961) per kg of body weight did not develop any lesions and demonstrated no adverse effects. " 12/01/2006 - "Cidofovir and hexadecyloxypropyl-cidofovir gave partial protection to mice infected with the virus when used at 50 and 100 mg/kg of body weight given as single treatments 24 h after virus exposure, whereas 2-amino-7-[(1,3-dihydroxy-2-propoxy)methyl]purine (compound S2242) was completely protective at 25, 50, and 100 mg/kg/day when given daily for 5 days. "
4.	Vaccinia 09/01/1997 - "Neither S2242 nor the natural substrates of TKs were phosphorylated by any of the vaccinia recombinants. " 01/01/1998 - "S2242 was not specifically phosphorylated by the HCMV-encoded UL-97 kinase in cells infected with a vaccinia/UL-97 recombinant. "
5.	Poxviridae Infections 01/01/2001 - "Compound S2242 and its oral prodrug H961 could be useful in treatment of orthopoxvirus infections."

Related Drugs and Biologics

1.	Cidofovir (Vistide)
2.	purine
3.	Ganciclovir (Cytovene)
4.	Foscarnet
5.	Thymidine
6.	Prodrugs
7.	Phosphotransferases (Kinase)
8.	Esters
9.	Antiviral Agents (Antivirals)
10.	Acyclovir (Aciclovir)